Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk

Journal of Medicinal Chemistry

Volumn 57, Issue 1, 2014, Pages 1-17

  Mantlo, Nathan B ^a   Escribano, Ana ^b  

^a ELI LILLY AND COMPANY   (United States)

^b ELI LILLY AND COMPANY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG EFFICACY; ELECTRON MICROSCOPY; HUMAN; LIPOPROTEIN METABOLISM; NONHUMAN; PROTEIN MODIFICATION; REVIEW;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BENZODIAZEPINES; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DISCOVERY; HUMANS; OXAZOLIDINONES; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892615575     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400574e     Document Type: Review

References (145)

1. Di Angelantonio, E.; Sarwar, N.; Perry, P.; Kaptoge, S.; Ray, K. K.; Thompson, A.; Wood, A. M.; Lewington, S.; Sattar, N.; Packard, C. J.; Collins, R.; Thompson, S. G.; Danesh, J. Major lipids, apolipoproteins, and risk of vascular disease JAMA 2009, 302 (18) 1993-2000
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344 (8934), 1383-1389.
3. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998, 339 (19), 1349-1357.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360 (9326), 7-22.
5. Downs, J. R.; Clearfield, M.; Weis, S.; Whitney, E.; Shapiro, D. R.; Beere, P. A.; Langendorfer, A.; Stein, E. A.; Kruyer, W.; Gotto, A. M., Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS JAMA 1998, 279 (20) 1615-1622
6. Sacks, F. M.; Pfeffer, M. A.; Moye, L. A.; Rouleau, J. L.; Rutherford, J. D.; Cole, T. G.; Brown, L.; Warnica, J. W.; Arnold, J. M.; Wun, C. C.; Davis, B. R.; Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators N. Engl. J. Med. 1996, 335 (14) 1001-1009
7. Shepherd, J.; Cobbe, S. M.; Ford, I.; Isles, C. G.; Lorimer, A. R.; MacFarlane, P. W.; McKillop, J. H.; Packard, C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N. Engl. J. Med. 1995, 333 (20) 1301-1307
8. Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L. E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E. H.; Keech, A.; Simes, J.; Collins, R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 2010, 376 (9753) 1670-1681
9. Barter, P.; Gotto, A. M.; LaRosa, J. C.; Maroni, J.; Szarek, M.; Grundy, S. M.; Kastelein, J. J.; Bittner, V.; Fruchart, J. C. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N. Engl. J. Med. 2007, 357, 1301-1310
10. Lavigne, P. M.; Karas, R. H. The current state of niacin in cardiovascular prevention: a systematic review and meta-regression J. Am. Coll. Cardiol. 2013, 61 (4) 440-446
11. The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N. Engl. J. Med. 2011, 365, 2255-2267
12. Sikorski, J. A. Oral cholesteryl ester transfer protein (CETP) inhibitors: A Potent approach for treating coronary artery disease J. Med. Chem. 2006, 49, 1-22
13. Berenson, A. Pfizer ends studies on drug for heart disease, The New York Times, Dec 3, 2006.
14. Barter, P. J.; Caulfield, M.; Eriksson, M.; Grundy, S. M.; Kastelein, J. J.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J.-C.; Waters, D. D.; Shear, C. L.; Revkin, J. H.; Buhr, K. A.; Fisher, M. R.; Tall, A. R.; Brewer, B. Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 2007, 357, 2109-2122
15. Tall, A. R.; Yvan-Charvet, L.; Wang, N. The failure of torcetrapib. Was is the molecule or the mechanism? Arterioscler., Thromb., Vasc. Biol. 2007, 27, 257-260
16. Hu, X.; Dietz, J. D.; Xia, C.; Knight, D. R.; Loging, W. T.; Smith, A. H.; Yuan, H.; Perry, D. A.; Keiser, J. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl Ester transfer protein inhibition Endocrinology 2009, 150 (5) 2211-2219
17. Forrest, M. J.; Bloomfield, D.; Briscoe, R. J.; Brown, P. N.; Cumiskey, A. M.; Ehrhart, J.; Hershey, J. C.; Keller, W. J.; Ma, X.; McPherson, H. E.; Messina, E.; Peterson, L. B.; Sharif-Rodriguez, W.; Siegl, P. K.; Sinclair, P. J.; Sparrow, C. P.; Stevenson, A. S.; Sun, S. Y.; Tsai, C.; Vargas, H.; Walker, M., III; West, S. H.; White, V.; Woltmann, R. F. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br. J. Pharmacol. 2008, 154 (7) 1465-1473
18. Schwartz, G. G.; Olsson, A. G.; Abt, M.; Ballantyne, C. M.; Barter, P. J.; Brumm, J.; Chaitman, B. R.; Holme, I. M.; Kallend, D.; Leiter, L. A.; Leitersdorf, E.; McMurray, J. J. V.; Mundl, H.; Nicholls, S. J.; Shah, P. K.; Tardif, J.-C.; Wright, R. S. For the dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome N. Engl. J. Med. 2012, 367, 2089-2099
19. Connolly, D. T.; McIntyre, J.; Heuvelman, D.; Remsen, E. E.; McKinnie, R. E.; Vu, L.; Melton, M.; Monsell, R.; Krul, E. S.; Glenn, K. Physical and kinetic characterization of recombinant human cholesteryl ester transfer protein Biochem. J. 1996, 320, 39-47
20. Qiu, X.; Mistry, A.; Ammirati, M. J.; Chrunyk, B. A.; Clark, R. W.; Cong, Y.; Culp, J. S.; E Danley, D. E.; Freeman, T. B.; Geoghegan, K. F.; Griffor, M. C.; Hawrylik, S. J.; Hayward, C. M.; Hensley, P.; Hoth, L. S.; Karam, G. A.; Lira, M. E.; Lloyd, D. B.; McGrath, K. M.; Stutzman-Engwall, K. J.; Subashi, A. K.; Subashi, T. A.; Thompson, J. F.; Wang, I.; Zhao, H.; Seddon, A. P. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules Nat. Struct. Mol. Biol. 2007, 14 (2) 106-113
21. Zhang, L.; Yan, F.; Zhang, S.; Lei, D.; Charles, M. A.; Cavigiolio, G.; Oda, M.; Krauss, R. M.; Weisgraber, K. H.; Rye, K. A.; Pownall, H. J.; Qiu, X.; Ren, G. Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein Nat. Chem. Biol. 2012, 8 (4) 342-349
22. Liu, S.; Mistry, A.; Reynolds, J. M.; Lloyd, D. B.; Griffor, M. C.; Perry, D. A.; Ruggeri, R. B.; Clark, R. W.; Qiu, X. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors J. Biol. Chem. 2012, 287 (44) 37321-37329
23. Niesor, E. J.; Magg, C.; Ogawa, N.; Okamoto, H.; von der Mark, E.; Matile, H.; Schmid, G.; Clerc, R. G.; Chaput, E.; Blum-Kaelin, D.; Huber, W.; Thoma, R.; Pflieger, P.; Kakutani, M.; Takahashi, D.; Cernick, G.; Maugeais, C. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport J. Lipid Res. 2010, 51, 3443-3454
24. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44 (1) 235-249
25. Perlman, M. E.; Murdande, S. B.; Gumkowski, M. J.; Shah, T. S.; Rodricks, C. M.; Thornton-Manning, J.; Freel, D.; Erhart, L. C. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib Int. J. Pharm. 2008, 351 (1-2) 15-22
26. Krishna, R.; Garg, A.; Panebianco, D.; Cote, J.; Bergman, A. J.; Van Hoydonck, P.; Laethem, T.; Kristien Van Dyck, K.; Chen, J.; Chavez-Eng, C.; Archer, L.; Lutz, R.; Hilliard, D.; Snyder, K.; Jin, B.; VanBortel, L.; Lasseter, K. C.; Al-Huniti, N.; Dykstra, K.; Keith Gottesdiener, K.; Wagner, J. A. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Br. J. Clin. Pharmacol. 2009, 68 (4) 535-545
27. Derks, M.; Kawamura, H.; Abt, M.; Meneses-Lorente, G.; Phelan, M.; Ishikawa, T. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers Clin. Ther. 2011, 33 (6) 754-765
28. Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R.; Robins, R. K. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics J. Chem. Inf. Comput. Sci. 1989, 29 (3) 163-172
29. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties J. Med. Chem. 2000, 43, 3714-3717
30. Loreau, L.; Gambert, P.; Lallemant, C. Immunospecific scintillation proximity assay of cholesteryl ester transfer protein activity Clin. Chem. 1995, 41 (6) 914-919
31. Bisgaier, C. L.; Minton, L. L.; Essenburg, A. D.; White, A.; Homan, R. Use of fluorescent cholesteryl ester microemulsions in cholesteryl ester transfer protein assays J. Lipid Res. 1993, 34 (9) 1625-1634
32. Ha, Y. C.; Barter, P. J. Differences in plasma cholesteryl ester transfer protein in sixteen vertebrate species Comp. Biochem. Physiol. B 1985, 71 (2) 265-269
33. Hayek, T.; Chajek-Shaul, T.; Walsh, A.; Agellon, L. B; Moulin, P.; Tall, A. R.; Breslow, J. L. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels J. Clin. Invest. 1992, 90, 505-510
34. Hariskrishnan, L. S.; Kamau, M. G.; Herpin, T. F.; Morton, G. C.; Liu, Y.; Cooper, C. B.; Salvati, M. E.; Qiao, J. X.; Wamg, T. C.; Adam, L. P.; Taylor, D. S.; Chen, A. Y. A.; Yin, X.; Seethala, R.; Peterson, T. L.; Nirschl, D. S.; Miller, A. V.; Weigelt, C. A.; Appiah, K. K.; O'Connell, J. C.; Lawrence, R. M. 2-Arylbenzoxazoles as novel cholesteryl ester transfer protein inhibitors: Optimization via array synthesis Bioorg. Med. Chem. Lett. 2008, 18, 2640-2644
35. Hunt, J. A. 2-Arylbenzoxazoles as novel cholesteryl ester transfer protein inhibitors: optimization via array synthesis Chemtracts 2008, 21, 179-183
36. Smith, C. J.; Ali, A.; Chen, L.; Hammond, M. L.; Anderson, M. S.; Chen, Y.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Milot, D. P.; Sparrow, C. P.; Wright, S. D.; Sinclair, P. J. 2-Arylbenzoxazoles as CETP inhibitors: Substitution of the benzoxazole moiety Bioorg. Med. Chem. Lett. 2010, 20, 346-349
37. Hunt, J. A.; Gonzalez, S.; Kallashi, F.; Hammond, M. L.; Pivnichny, J. V.; Tong, X.; Xu, S. S.; Anderson, M. S.; Chen, Y.; Eveland, S. S.; Hyland, S. A.; Milot, D. P.; Sparrow, C. P.; Wright, S. D.; Sinclair, P. J. 2-Arylbenzoxazoles as CETP inhibitors: Substitution and modification of the α-alkoxyamide moiety Bioorg. Med. Chem. Lett. 2010, 20, 1019-1022
38. Kallashi, F.; Kim, D.; Kowalchick, J.; Park, Y. J.; Hunt, J. A.; Ali, A.; Smith, C. J.; Hammond, M. L.; Pivnichny, J. V.; Tong, X.; Xu, S. S.; Anderson, M. S.; Chen, Y.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Milot, D. P.; Cumiskey, A.-M.; Latham, M.; Peterson, L. B.; Rosa, R.; Sparrow, C. P.; Wright, S. D.; Sinclair, P. J. 2-Arylbenzoxazoles as CETP inhibitors: Raising HDL-C in cynoCETP transgenic mice Bioorg. Med. Chem. Lett. 2011, 21, 558-561
39. Sweis, R. F.; Hunt, J. A.; Kallashi, F.; Hammond, M. L.; Chen, Y.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Milot, D. P.; Cumiskey, A.-M.; Latham, M.; Rosa, R.; Peterson, L.; Sparrow, C. P.; Wright, S. D.; Anderson, M. S.; Sinclair, P. J. 2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: Scaffold design and advancement in HDLc-raising efficacy Bioorg. Med. Chem. Lett. 2011, 21, 1890-1895
40. Sweis, R. F.; Hunt, J. A.; Sinclair, P. J.; Chen, Y.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Milot, D. P.; Cumiskey, A.-M.; Latham, M.; Rosa, R.; Peterson, L.; Sparrow, C. P.; Wright, S. D.; Anderson, M. S. 2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: Attenuation of hERG binding and improved HDLc-raising efficacy Bioorg. Med. Chem. Lett. 2011, 21, 2597-2600
41. Lu, Z.; Napolitano, J. B.; Theberge, A.; Ali, A.; Hammond, M. L.; Tan, E.; Tong, X.; Xu, S. S.; Latham, M. J.; Peterson, L. B.; Anderson, M. S.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Eveland, S. S.; Chen, Y.; Sparrow, C. P.; Wright, S. D.; Sinclair, P. J. Design of a novel class of biphenyl CETP inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 7469-7472
42. Ali, A.; Bohn, J.; Deng, Q.; Lu, Z.; Sinclair, P. J.; Taylor, G. E.; Thompson, C. F.; Quraishi, N. CETP Inhibitors. Patent application WO2005/100298, Oct 25, 2005.
43. Chen, Y.-H.; Lu, Z.; Sinclair, P. J. CETP Inhibitors. Patent application WO2007/047591, Apr 26, 2007.
44. Ali, A.; Sinclair, P. J. Cholesteryl Ester Transfer Protein Inhibitors. Patent application WO2007/041494, Apr 12, 2007.
45. Ali, A.; Napolitano, J. M.; Deng, Q.; Lu, Z.; Sinclair, P. J.; Taylor, G. E.; Thompson, C.; Quraishi, N.; Smith, C.; Hunt, J. A.; Dowst, A. A.; Chen, Y.-H.; Li, H. CETP Inhibitors. Patent application WO2006/014413, Feb 9, 2006.
46. Ali, A.; Napolitano, J. M.; Deng, Q.; Lu, Z.; Sinclair, P. J.; Taylor, G. E.; Thompson, C.; Quraishi, N.; Smith, C.; Hunt, J. A. CETP Inhibitors. Patent application WO2006/014357, Feb 9, 2006.
47. Ali, A.; Lu, Z.; Sinclair, P. J.; Taylor, G, E.; Thompson, C. F.; Smith, C. J.; Dowst, A. A.; Chen, Y.-H. CETP Inhibitors. Patent application WO2007/081571, Jul 19, 2007.
48. Ali, A.; Lu, Z.; Sinclair, P. J.; Chen, Y.-H.; Smith, C. J.; Li, H.; Thompson, C. F. CETP Inhibitors. Patent application WO2007/081569, Jul 19, 2007.
49. Ali, A.; Lu, Z.; Sinclair, P. J.; Chen, Y.-H.; Smith, C. J.; Li, H. CETP Inhibitors. Patent application WO2007/079186, Jul 12, 2007.
50. Thompson, C. F.; Ali, A.; Quraishi, N.; Lu, Z.; Hammond, M. L.; Sinclair, P. J; Anderson, M. S.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Milot, D. P.; Sparrow, C. P.; Wright, S. D. Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein Med. Chem. Lett 2011, 2, 424-427
51. Ali, A.; Sinclair, P. J.; Taylor, G. E. Cholesteryl Ester Transfer Protein Inhibitors. Patent application WO2007/081570, Jul 19, 2007.
52. Smith, C. J.; Ali, A.; Hammond, M. L.; Li, H.; Lu, Z.; Napolitano, J. B.; Taylor, G. E.; Thompson, C. F.; Anderson, M. S.; Chen, Y.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Milot, D. P.; Sparrow, C. P.; Wright, S. D.; Cumiskey, A.-M.; Latham, M. J.; Peterson, L. B.; Rosa, R.; Pivnichny, J. V.; Tong, X.; Xu, S. S.; Sinclair, P. J. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib J. Med. Chem. 2011, 54, 4880-4895
53. Lu, A.; Chen, Y.; Napolitano, J. B.; Taylor, G. E.; Ali, A.; Hammond, M. L.; Deng, Q.; Tan, E.; Tong, X.; Xu, S. S.; Latham, M. J.; Peterson, L. B.; Anderson, M. S.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Milot, D. P.; Chen, Y.; Sparrow, C. P.; Wright, S. D.; Sinclair, P. J. SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 199-203
54. Wang, Y.; Zhang, Y.; Huang, Q. Oxazolidinone-Like Compounds and Their Application as CETP Inhibitor for Preventing and Treating Atherosclerosis. Patent application CN102516237, Jun 27, 2012.
55. Tan, E. Y.; Hartman, G.; Chen, Q.; Pereira, A.; Bradley, S.; Doss, G.; Zhang, A.; Ho, J. Z.; Braun, M. P.; Dean, D. C.; Tang, W.; Kumar, S. Pharmacokinetics, metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys Drug Metab. Dispos. 2010, 38, 459-473
56. Kumar, S.; Tan, E. Y.; Hartman, G.; Biddle, Z.; Bergman, A. J.; Dru, J.; Ho, J. Z.; Jones, A. N.; Staskiewicz, S. J.; Braun, M. P.; Karanam, B.; Dean, D. C.; Gendrano, I. N.; Graves, M. W.; Wagner, J. A.; Krishna, R. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans Drug Metab. Dispos. 2010, 38, 474-483
57. Dansky, H. M.; Bloomfield, D.; Gibbons, P.; Liu, S.; Sisk, C. M.; Tribble, D.; McKenney, J. M.; Littlejohn, T. W., III; Mitchel, Y. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia Am. Heart J. 2011, 162, 708-716
58. Krishna, R.; Bergman, A. J.; Jin, B.; Fallon, M.; Cote, J.; Van Hoydonck, P.; Laethem, T.; Gendrano, I. N., III; Van Dyck, K.; Hilliard, D.; Laterza, O.; Snyder, K.; Chavez-Eng, C.; Lutz, R.; Chen, J.; Bloomfield, D. M.; De Smet, M.; Van Bortel, L. M.; Gutierrez, M.; Al-Huniti, N.; Dykstra, K.; Gottesdiener, K. M.; Wagner, J. A. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Clin. Pharm. Ther. 2008, 84, 679-683
59. Krishna, R.; Bergman, A. J.; Jin, B.; Garg, A.; Roadcap, B.; Chiou, R.; Dru, J.; Cote, J.; Laethem, T.; Wang, R. W.; Didolkar, V.; Vets, E.; Gottesdiener, K.; Wagner, J. A. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers J. Clin. Pharm. 2009, 49, 80-87
60. Bloomfield, D.; Carlson, G. L.; Sapre, A.; Tribble, D.; McKenney, J. M.; Littlejohn, T. W.; McCrary Sisk, C.; Mitchel, Y.; Pasternak, R. C. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am. Heart J. 2009, 157, 352-360
61. Cannon, C. P.; Shah, S.; Dansky, H. M.; Davidson, M.; Brinton, E. A.; Gotto, A. M., Jr.; Phil, D.; Stepanavage, M.; Liu, S. X.; Gibbons, P.; Ashraf, T. B.; Zafarino, J.; Mitchel, Y.; Barter, P. Safety of anacetrapib in patients with or at high risk for coronary heart disease N. Engl. J. Med. 2010, 363, 2406-2415
62. Thompson, C. F.; Sweis, R. F. Pyridyl Oxazolidinone CETP Inhibitor. Patent application WO2011/028395, March 10, 2011.
63. Lu, Z.; Chen, Y.-H.; Smith, C.; Li, H.; Thompson, C. F.; Sweis, R.; Sinclair, P. J.; Kallashi, F.; Hunt, J.; Adamson, S. E.; Dong, G.; Ondeyka, D. L.; Qian, X.; Sun, W.; Vachal, P.; Zhao, K. Cyclic Amine Substituted Oxazolidinone CETP Inhibitor. Patent application WO2012/058187, May 3, 2012.
64. Lee, S.; Oh, J.; Lee, J.; Lee, J.; Bae, S.; Ha, N.; Lee, S. Cycloalkenyl Aryl Derivatives for CETP Inhibitor. Patent application WO2012/141487, Oct 18, 2012.
65. Escribano, A. M.; Fernandez, M.-C.; Mantlo, N. B.; Mateo Herranz, A. I.; Martin de la Nava, E. M.; Wang, X. Compounds and Methods for Treating Dyslipidemia. Patent application WO2006/012093, Feb 2, 2006.
66. Escribano, A.; Mateo, A. I.; Martin de la Nava, E. M.; Mayhugh, D. R.; Cockerham, S. L.; Beyer, T. P.; Schmidt, R. J.; Cao, G.; Zhang, Y.; Jones, T. M.; Borel, A. G.; Sweetana, S. A.; Cannady, E. A.; Mantlo, N. B. Design and Synthesis of New Tetrahydroquinolines Derivativeas as CETP Inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 3671-3675
67. Jones, Z.; Groneberg, R.; Drew, M.; Eary, C. T. Inhibitors of Cholesteryl Transfer Protein. Patent application US2005/0282812, Dec 22, 2005.
68. Eary, C. T.; Jones, Z. S.; Groneberg, R. D.; Burgess, L. E.; Mareska, D. A.; Drew, M. D.; Blake, J. F.; Laird, E. R.; Balachari, D.; O'Sullivan, M.; Allen, A.; Marsh, V. Tetrazole and ester substituted tetrahydroquinoxalines as potent cholesteryl ester transfer protein inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 2608-2613
69. Bell, M. G.; Cao, G.; Escribano, A. M.; Fernandez, M.-C.; Lander, P. A.; Mantlo, N. B.; Martin de la Nava, E. M.; Mateo Herranz, A. I.; Mayhugh, D. R.; Wang, X. Compounds and Methods for Treating Dyslipidemia. Patent application WO2005/097806 Oct 20, 2005.
70. Fernandez, M.-C.; Escribano, A.; Mateo, A. I.; Parthasarathy, S.; Martin de la Nava, E. M.; Wang, X.; Cockerham, S. L.; Beyer, T. P.; Schmidt, R. J.; Cao, G.; Zhang, Y.; Jones, T. M.; Borel, A.; Sweetana, S. A.; Cannady, E. A.; Stephenson, G.; Frank, S.; Mantlo, N. B. Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 3056-3062
71. Kubota, H.; Sugahara, M.; Furukawa, M.; Takano, M.; Motomura, D. Tetrahydroquinoline Derivatives and a Process for Preparing the Same. Patent application WO2005/095409, Jan 13, 2005.
72. Kubota, H.; Nakamura, Y.; Higashijima, T.; Yamamoto, Y.; Oka, K.; Igarahsi, S. Tetrahydronaphthyridine Derivatives and a Process for Preparing the Same. Patent application WO2005/095395, Oct 15, 2005.
73. Cao, G.; Escribano, A. M.; Fernandez, M.-C.; Fields, T.; Gernert, D. L.; Cioffi, C. L.; Herr, R. J.; Mantlo, N. B.; Martin de la Nava, E. M.; Mateo Herranz, A. I.; Mayhugh, D. R.; Wang, X. Compounds and Methods for Treating Dyslipidemia. Patent application WO2005/037796, Apr 28, 2005.
74. Chen, X.; Cioffi, C. L.; Dinn, S. R.; Escribano, A. M.; Fernandez, M.-C.; Field, T.; Herr, R. J.; Mantlo, N. B.; Martin de la Nava, E. M.; Mateo Herranz, A. I; Parthasarathy, S.; Wang, X. Compounds and Methods for Treating Dyslipidemia. Patent application WO2006/002342, Jan 5, 2006.
75. Mantlo, N. B.; Fields, T.; Wang, X.; Fernandez, M.-C.; Mateo, A. I.; Escribano, A.; Martin de la Nava, E. M.; Parthasarathy, S.; Giese, M. W.; Carson, M.; Beyer, T. P.; Cockerham, S. L.; Cao, G.; Kovach, K.; Sweetana, S.; Borel, A.; Jones, T. M.; Cannady, E. A.; Cioffe, C.; Chen, X.; Dinn, S. Azepine Inhibitors of Plasma Cholesteryl Ester Transfer Protein. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, Mar 25-29, 2007; MEDI-222.
76. Xinchao, C.; Frank, S. C.; Remick, D. M.; Pedersen, S. W. Trans-4-[[(5 S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino] -2,3,4,5-tetrahydro-7,9-dimethyl-1 H -1-benzazepin-1-yl]methyl]- cyclohexanecarboxylic Acid for Treatment of Cardiovascular Diseases. Patent application US2010/0331309, Dec 30, 2010.
77. Cao, G.; Beyer, T. P.; Zhang, Y.; Schmidt, R. J.; Chen, Y. Q.; Cockerham, S. L.; Zimmerman, K. M.; Karathanasis, S. K.; Cannady, E. A.; Fields, T.; Mantlo, N. B. Evacetrapib is a novel, potent and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure J. Lipid Res. 2011, 52, 2169-2176
78. Nicholls, S. J.; Brewer, H. B.; Kastelein, J. J. P.; Krueger, K. A.; Wang, M.-D.; Shao, M.; Hu, B.; McErlean, E.; Nissen, S. E. Effects of the CETP inhibitor Evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol J. Am. Med. Ass. 2011, 306, 2099-2109
79. Riesmeyer, J. S. Evacetrapib: Lipoprotein Profile and Clinical Trial of a Novel CETP Inhibitor, Cardiovascular Research Technologies 2013 Atherosclerosis, Plaque Imaging and Lipid Therapy, Washington DC, MD, Feb 23-26, 2013.
80. Hariskrishnan, L. S.; Finlay, H. J.; Qiao, J. X.; Kamau, M. G.; Jiang, J.; Wang, T. C.; Li, J.; Cooper, C. B.; Poss, M. A.; Adam, L. P.; Taylor, D. S.; Chen, A. Y. A.; Yin, X.; Sleph, P. G.; Yang, R. Z.; Sitkoff, D. F.; Galella, M. A.; Nirschl, D. S.; Kirk, K. V.; Miller, A. V.; Huang, C. S.; Chang, M.; Chen, X.-Q.; Salvati, M. E.; Wexler, R. R.; Lawrence, R. M. Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors J. Med. Chem. 2012, 55, 6162-6175
81. Miller, M. M.; Liu, Y.; Jiang, J.; Johnson, J. A.; Kamau, M.; Nirschl, D. S.; Wang, Y.; Hariskrishnan, L. S.; Taylor, D. S.; Chen, A. Y. A.; Yin, X.; Seethala, R.; Peterson, T. L.; Zvyaga, T.; Zhang, J.; Huang, C. S.; Wexler, R. R.; Poss, M. A.; Lawrence, R. M.; Adam, L. P.; Salvati, M. E. Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 6503-6508
82. Jiang, J.; Finlay, H.; Johnson, J.; Salvati, M.; Hariskrishnan, L.; Kamau, M.; Qiao, J.; Wang, T.; Taylor, D.; Chen, A.; Yin, X.; Huang, C.; Chang, M.; Sleph, P.; Li, J.; Hennan, J.; Levesque, P.; Adam, L.; Wexler, R. Hydroxyl 1,2-Diphenylethanamine Analogs as Potent Cholesterol Ester Transfer Protein Inhibitors, Abstracts of Papers, 244th ACS National Meeting & Exposition, Philadelphia, PA, Aug 19-23, 2012, MEDI-130.
83. Salvati, M. E.; Johnson, J. A.; Xu, N. Extended Amino CETP Inhibitors. Patent application WO2008/070496, Jun 12, 2008.
84. Reinhard, E.; Wang, J. L.; Durley, R. C.; Fobian, Y. M.; Grapperhaus, M. L.; Hickory, B. S.; Massa, M. A.; Norton, M. B.; Promo, M. A.; Tollefson, M. B.; Vernier, W. F.; Connolly, D. T.; Witherbee, B. J.; Melton, M. A.; Regina, K. L.; Smith, M. E.; Sikorski, J. A. Discovery of simple picomolar inhibitor of cholesteryl ester transfer protein J. Med. Chem. 2003, 46, 2152-2168
85. Rano, T.; Kuo, G.-H.; Sieber-McMaster, E.; Demarest, K. T.; Pelton, P.; Wang, A. 1,2,3,4-Tetrahydro-quinoline Derivatives as CETP Inhibitors. Patent application WO2008/079427, Jul 3, 2008.
86. Rano, T.; Sieber-McMaster, E.; Pelton, P. D.; Yang, M.; Demarest, K. T.; Kuo, G.-H. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform Bioorg. Med. Chem. Lett. 2009, 19, 2456-2460
87. Kuo, G.-H.; Rano, T.; Pelton, P.; Demarest, K. T.; Gibbs, A. C.; Murray, W. V.; Damiano, B. P.; Connelly, M. A. Design, synthesis and biological evaluation of (2 R,αS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl] -5-[3-(trifluoromethoxy)-phenyl]-α-(trifluoromethyl)-1(2 H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor J. Med. Chem. 2009, 52, 1768-1772
88. Rano, T.; Kuo, G.-H.; Sieber-McMaster, E.; Demarest, K. T.; Pelton, P.; Wang, A. 1,2,3,4-Tetrahydro-quinoline Derivatives as CETP Inhibitors. Patent application US2007/0265304, Nov 15, 2007.
89. Connelly, M. A.; Parry, T. J.; Giardino, E. C.; Huang, Z.; Cheung, W.; Chen, C.; Cools, F.; Van der Linde, H.; Gallacher, D. J.; Kuo, G.-H.; Sarich, T. C.; Demarest, K. T.; Damiano, B. P. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition J. Cardiovasc. Pharmacol. 2010, 55, 459-468
90. Sarich, T. C.; Connelly, M. A.; Schranz, D. B.; Ghosh, A.; Manitpisitkul, P.; Leary, E. T.; Rothenberg, P.; Demarest, K. T.; Damiano, B. P. Phase 0 study of the inhibition of cholesteryl ester transfer protein activity of JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans Int. J. Clin. Pharm. Ther. 2012, 50, 584-594
91. Kuo, G.-H.; Wang, A.; Rano, T.; Prouty, C.; Demarest, K. T.; Pelton, P. 3,4-Dihydro-2 H -benzo[1,4]oxazine and Thiazine Derivatives as CETP Inhibitors. Patent application WO2007/134149, Nov 22, 2007.
92. Wang, A.; Prouty, C. P.; Pelton, P. D.; Yong, M.; Demarest, K. T.; Murray, W. V.; Kuo, G.-H. Synthesis and discovery of 2,3-dihydro-3,8- diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1432-1435
93. Kuo, G.-H.; Wang, A.; Rano, T.; Prouty, C.; Demarest, K T.; Pelton, P. 3,4-Dihydro-2H-benzo[1,4]oxazine and Thiazine Derivatives as CETP Inhibitors. Patent application US2007/0265252, Nov 15, 2007.
94. Anand, R.; Colandrea, V. J.; Reiter, M.; Vachal, P.; Zwicker, A.; Wilson, J. E.; Zhang, F.; Zhao, R. Benzopiperazine Derivatives as CETP Inhibitors. Patent application WO2013/028382, Feb 28, 2013.
95. Schmidt, G.; Brandes, A.; Angerbauer, R.; Logers, M.; Muller-Gliemann, M.; Schmeck, C.; Bremm, K.-D.; Bischoff, H.; Schmidt, D.; Schuhmacher, J.; Giera, H.; Paulsen, H.; Naab, P.; Conrad, M.; Stoltefuss, J. Cycloalkano-pyridine as CETP Inhibitors. Patent application EP818448, Jan 14, 1998.
96. Schmidt, G.; Brandes, A.; Angerbauer, R.; Logers, M.; Muller-Gliemann, M.; Schmeck, C.; Bremm, K.-D.; Bischoff, H.; Schmidt, D.; Schuhmacher, J.; Giera, H.; Paulsen, H.; Naab, P.; Conrad, M.; Stoltefuss, J. Cycloalkano-pyridines. Patent application US6207671, Mar 27, 2001.
97. Schmeck, C.; Gielen-Haertwig, H.; Vakalopoulos, A.; Bischoff, H.; Li, V.; Wirtz, G.; Weber, O. Novel tetrahydrochinoline derived CETP inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1740-1743
98. Bischoff, H.; Gielen-Haertwig, H.; Li, V.; Schmeck, C.; Thutewohl, M.; Vakalopoulos, A.; Weber, O.; Wuttke, M. 4-Cycloalkyl-Substituted Tetrahydrochinoline Derivatives and Use Thereof of Medicaments. Patent application WO2006/063828, Jun 22, 2006.
99. Bischoff, H.; Gielen-Haertwig, H.; Li, V.; Schmeck, C.; Thutewohl, M.; Vakolopoulos, A.; Weber, O.; Wuttke, M. Preparation of a Quinolinol Derivative Useful for the Treatment of Cardiovascular Diseases and as an Inhibitor of Cholesterol Ester Transfer Protein. Patent application DE102004061000, Jun 22, 2006.
100. Boettcher, M.-F.; Heinig, R.; Schmeck, C.; Kohlsdorfer, C.; Ludwig, M.; Schaefer, A.; Gelfer-Peukert, S.; Wensing, G.; Weber, O. Single dose pharmacokinetics, pharmacodynamisc, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein Br. J. Clin. Pharmacol. 2012, 73, 210-218
101. Schmeck, C.; Bischoff, H.; Li, V.; Lustig, K.; Thutewohl, M.; Vakalopoulos, A.; Weber, O. Substituted Chromanol Derivatives and Their Use. Patent application WO2007/107243, Sep, 27, 2007.
102. Vakalopoulos, A.; Schmeck, C.; Thutewohl, M.; Li, V.; Bischoff, H.; Lustig, K.; Weber, O.; Paulsen, H.; Elias, H. Chromanol derivatives-A novel class of CETP inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 488-491
103. Wagner, H.; Berta, D.; Giovannini, R.; Mazzacani, A.; Streicher, R.; Fuchs, K. Tricyclic Pyridine Derivatives, Medicaments Containing Such Compounds, Their Use and Process for Their Preparation. Patent application WO2009/109549, Sep 11, 2009.
104. Wagner, H.; Berta, D.; Fuchs, K.; Giovannini, R.; Hamprecht, W.; Konetzki, I.; Streicher, R.; Trieselmann, T. Tricyclic Pyridine Derivatives, Medicaments Containing Such Compounds, Their Use and Process for Their Preparation. Patent application WO2011/101424, Aug 25, 2011.
105. Wagner, H.; Berta, D.; Fuchs, K.; Giovannini, R.; Hamprecht, W.; Konetzki, I.; Streicher, R.; Trieselmann, T. Tricyclic Pyridine Derivatives, Medicaments Containing Such Compounds, Their Use and Process for Their Preparation. Patent application WO2012/110599, Aug 23, 2012.
106. Trieselmann, T.; Hamprecht, W.; Wagner, H. Furo[3,4-c]quinoline Derivatives, Medicaments Containing Such Compounds, Their Use and Process for Their Preparation. Patent application WO2013/024130, Feb 21, 2013.
107. Ostermeier, M.; Gerlach, K.; Sieger, P. Crystalline Forms of Octahydro-3H-spiro[furo[3,4-c]quinoline-1,4′-pyran]-9-ol. Patent application WO2013/024149, Feb 21, 2013.
108. Nakamura, T.; Namiki, H.; Terasaka, N.; Shima, A.; Hagihara, M.; Iwase, N.; Takata, K.; Kikuchi, O.; Tsuboike, K.; Setoguchi, H.; Yoneda, K.; Sunamoto, H.; Ito, K. Substituted Pyridine Compounds. Patent application WO2012/005343, Jan 12, 2012.
109. Terasaka, N. Ds-1442b is a novel, potent CETP inhibitor that reduces atherosclerosis by HDL elevation and non-HDL reduction Circulation 2012, 126, A11806
110. Maeda, K.; Namagori, H.; Nakamura, H.; Shinkai, H.; Suzuki, Y.; Takahashi, D.; Taniguchi, T. Dibenzylamine Compound and Medicinal Use Thereof. Patent application WO2004/020393, Mar 11, 2004.
111. Baruah, A.; De, D.; Khanna, I. K.; Pillarisetti, S.; Maitra, S.; Alexander, C. W.; Sreenu, J.; Dager, I. Novel Benzylamine Derivatives as CETP Inhibitors. Patent application WO2006/073973, Jul, 13, 2006.
112. Baruah, A.; Alikunju, S. Substituted Heterocyclic Amine Compounds as Cholesteryl Ester-Transfer Protein (CETP) Inhibitors. Patent application WO2013/024358, Feb 21, 2013.
113. Mallikarjuna, R. D.; Abhijit, B.; Shivva, V.; Mangapathiraju, T.; Sumera, H.; Sesha, S. M.; Shanavas, A.; Vasu, S.; Kent, A.; Rajinder, K. Safety, tolerability, pharmacokinetic and pharmacodynamic profile of multiple-doses of DRL-17822, a potent cholesteryl ester transfer protein inhibitor in healthy male subjects Circulation 2010, 122, A13981
114. Sakaki, J.; Kishida, M.; Matsuura, N.; Umemura, I.; Kawahara, E.; Yamada, K.; Konishi, K.; Iwaki, Y.; Imase, H.; Miyake, T. Pyridinyl Amine Derivatives as Inhibitors of Cholesteryl Ester Transfer Protein (CETP). Patent application WO2007/073934, Jul 5, 2007.
115. Kishida, M.; Matsuura, N.; Imase, H.; Iwaki, Y.; Umemura, I.; Ohmori, O.; Kawahara, E. Bicyclic Derivatives as CETP Inhibitors. Patent application WO2007/128568, Nov 15, 2007.
116. Konishi, K.; Iwaki, Y. Benzylamine Derivatives as CETP Inhibitors. Patent application WO2007/132906, Nov 22, 2007.
117. Imase, H.; Kishida, M. Heterocyclic Derivatives as CETP Inhibitors. Patent application WO2008/058961, May 22, 2008.
118. Imase, H.; Kishida, M. Organic Compounds. Patent application WO2008/058967, May 22, 2008.
119. Imase, H.; Iwaki, Y.; Kawanami, T.; Miyake, T.; Mogi, M.; Ohmori, O.; Qin, H.; Umemura, I.; Yamada, K.; Yasoshima, K. Amino-piperidine Derivatives as CETP Inhibitors. Patent application WO2008/009435, Jan 24, 2008.
120. Mogi, M.; Yamada, K.; Yasoshima, K.; Kawanami, T.; Umemura, I.; Iwaki, Y.; Qin, H.; Imase, H. 4-Benzylamino-1-carboxyacyl-piperidine Derivatives as CETP Inhibitors Useful for the Treatment of Diseases Such as Hyperlipidemia or Arteriosclerosis. Patent application WO2009/059943 May 14, 2009.
121. Mogi, M.; Kawanami, T.; Yamada, K.; Yasoshima, K.; Imase, H.; Miyake, T.; Ohmori, O. 4-1,2-Disubstituted-4-benzylamino-pyrrolidine Derivatives as CETP Inhibitors Useful for the Treatment of Diseases Such as Hyperlipidemia or Arteriosclerosis. Patent application WO2009/071509, Jun 11, 2009.
122. Arai, Y.; Brousseau, M. E.; Gu, J.; Hayashi, T.; Mitani, H.; Mogi, M.; Nonomura, K.; Yamada, K. Method of Treating Arteriosclerosis in High Triglyceride Subjects. Patent application WO2013/008164, Jan 17, 2013.
123. Nakamura, Y.; Hayashi, N.; Higashijima, T.; Kubota, H.; Oka, O. Trisubstituted Amine Compounds as Inhibitors of Cholesteryl Ester Transfer Protein CETP. Patent application WO2007/088996, Aug, 9, 2007.
124. Nakamura, Y.; Hayashi, N.; Higashijima, T.; Kubota, H.; Oka, O. Trisubtituted Amine Compound. Patent application WO2007/088999, Aug 9, 2007.
125. Dezima Pharma Press Realease, Naarden, The Netherlands, Feb 28, 2013. Dezima Pharma raises €14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001. http://www.dezimapharma.com/dezima-pharma-raises-14.2m.pdf
126. Ohgiya, T.; Miura, T.; Okuda, A.; Arai, Y.; Yamazaki, K.; Aoki, T.; Miyosawa, K.; Shibata, H.; Shibuya, K. Novel Pyrimidine Compound Having Dibenzylamine Structure, and Medicine Comprising the Compound. Patent application WO2008/129951, Oct 30, 2008.
127. Ohgiya, T.; Miura, T.; Okuda, A.; Arai, Y.; Yamazaki, K.; Aoki, T.; Miyosawa, K.; Shibata, H.; Shibuya, K. Novel Pyrimidine Compound Having Benzyl(heterocyclicmethyl)amine Structure, and Pharmaceutical Product Containing the Same. Patent application WO2008/111604, Sep 18, 2008.
128. Ohgiya, T.; Miura, T.; Okuda, A.; Arai, Y.; Yamazaki, K.; Aoki, T.; Miyosawa, K.; Shibata, H.; Shibuya, K. Novel Pyrimidine Compound Having Benzyl(pyridylmethyl)amine Structure, and Pharmaceutical Product Comprising the Compound. Patent application WO2008/018529, Feb 14, 2008.
129. Conte, A.; Kuehne, H.; Luebbers, T.; Mattei, P.; Maugeais, C.; Mueller, W.; Pflieger, P. Heteroaryl and Benzyl Amide Compounds. Patent application US2007/0185058, Aug 9, 2007.
130. Faeh, C.; Kuehne, H.; Luebbers, T.; Mattei, P.; Maugeais, C.; Mueller, W.; Pflieger, P. Heteroaryl and Benzyl Amide Compounds. Patent application US2007/0185113, Aug 9, 2007.
131. Conte, A.; Kuehne, H.; Luebbers, T.; Mattei, P.; Maugeais, C.; Mueller, W.; Pflieger, P. Heteroaryl Carboxamide Compounds. Patent application US2007/0185152, Aug 9, 2007.
132. Kuehne, H.; Luebbers, T.; Mattei, P.; Maugeais, C.; Mueller, W.; Pflieger, P.; Scalone, M. Heterobicyclic Amide Compounds. Patent application US2007/0185154, Aug 9, 2007.
133. Conte, A.; Kuehne, H.; Luebbers, T.; Mattei, P.; Maugeais, C.; Mueller, W.; Pflieger, P. Anthranilamide/2-amino-heteroarene Carboxamide Derivatives. Patent application WO2007/090752, Aug 16, 2007.
134. Khalaf, R. A.; Sheikha, G. A.; Bustanji, Y.; Taha, M. O. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration Eur. J. Med. Chem. 2010, 45, 1598-1617
135. Sheikha, G. A.; Khalaf, R. A.; Melhem, A.; Albadawi, G. Design, synthesis and biological evaluation of benzylamino-methanone based cholesteryl ester transfer protein inhibitors Molecules 2010, 15, 5721-5733
136. Khalaf, R. A.; Sheikha, G. A.; Al-Sha'er, M.; Albadawi, G.; Taha, M. Design, synthesis and biological evaluation of sulfonic acid ester and benzenesulfonamide derivatives as potential CETP inhibitors Med. Chem. Res. 2012, 21, 3669-3680
137. Matsuura, F.; Wang, N.; Chen, W.; Jiang, X.-C.; Tall, A. R. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway J. Clin. Invest. 2006, 116 (5) 1435-1442
138. Yvan-Charvet, L.; Kling, J.; Pagler, T.; Li, H.; Hubbard, B.; Fisher, T.; Sparrow, C. P.; Taggart, A. K.; Tall, A. R. Cholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib Arterioscler., Thromb., Vasc. Biol. 2010, 30 (7) 1430-1438
139. Zhong, S.; Sharp, D. S.; Grove, J. S.; Bruce, C.; Yano, K.; Curb, J. D.; Tall, A. R. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels J Clin. Invest. 1996, 97, 2917-2923
140. Curb, J. D; Abbott, R. D.; Rodriguez, B. L.; Masaki, K.; Chen, R.; Sharp, D. S.; Tall, A. R. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly J. Lipid Res. 2004, 45, 948-953
141. Barter, P. J.; Rye, K.-A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk J. Lipid Res. 2012, 53, 1755-1766
142. Khera, A. V.; Cuchel, M.; de la Llera-Moya, M.; Rodrigues, A.; Burke, M. F.; Jafri, K.; French, B. C.; Phillips, J. A.; Mucksavage, M. L.; Wilensky, R. L.; Mohler, E. R.; Rothblat, G. H.; Rader, D. J. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N. Engl. J. Med. 2011, 364 (2) 127-135
143. Zhao, H. Lead optimization in the nondrug-like space Drug Discovery Today 2011, 16, 158-163
144. Anacetrapib: DEFINE clinical trial. Evacetrapib ACCELERATE clinical trial. Retrieved April 2013, from http://clinicaltrials.gov.
145. Merck & Co., Inc. Form 10-K for the Fiscal Year Ended December 31, 2012, p 18; retrieved from http://www.merck.com/investors/financials/form-10-k- 2012.pdf.